IDIX Positive Results With IDX184 From Interim Analysis of Phase IIa Hepatitis C Study
Idenix Pharmaceuticals Reports Positive Results With IDX184 From Interim Analysis of Phase IIa Hepatitis C Study -- IDX184 50 and 100 mg cohorts in combination with pegylated interferon and ribavirin (PegIFN/RBV) demonstrated a favorable safety profile and potent antiviral activity at 14 days -- Fifty percent of subjects receiving a total daily dose of 100 mg IDX184 achieved undetectable virus levels by Day 14 -- Study continuing with enrollment of 150 mg cohort
Market Data 
Markets 
AI
